DURYSTA®
(bimatoprost intracameral implant) 10 mcg

A RELIABLE TREATMENT CHOICE TO LOWER EYE PRESSURE[1]

Not an actual DURYSTA® patient.

CHECK "✓" THE BOX IF THE STATEMENT APPLIES TO YOU

- ☐ You have received laser treatment for your eye pressure
- ☐ It can be difficult getting drops into your eyes
- ☐ It's challenging to remember to take your drops
- ☐ You have a sensitivity to preservatives
- ☐ You're interested in other treatment options

If you've checked any of the boxes above, ask your doctor if DURYSTA® is right for you

As DURYSTA® dissolves, it automatically releases medicine[1,2]



The implant is tiny and preservative free[1,3]

Actual size of the DURYSTA® implant.

One DURYSTA® implant works for several months[1,2]

USES

DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure (also called intraocular pressure, or IOP) in patients with open angle glaucoma or high eye pressure (ocular hypertension).

IMPORTANT SAFETY INFORMATION

DURYSTA should not be used if:

- You have any infection or suspected infection in your eye or surrounding eye area
- You have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally and can cause vision problems
- You have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant)
- The sack that surrounds the lens of your eye (posterior lens capsule) is missing or torn
- You are allergic to any of its ingredients

Please see additional Important Safety Information on the back page.

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf

DURYSTA®
(bimatoprost intracameral implant) 10 mcg

WHAT PATIENTS ARE SAYING ABOUT TREATMENT WITH DURYSTA®

—Actual DURYSTA® patient quotes

Not actual DURYSTA® patients.

IMPORTANT SAFETY INFORMATION (continued)

DURYSTA® (bimatoprost intracameral implant) may cause side effects involving the cornea, including increased risk of loss of cells from the inner layer of the cornea. You should not receive DURYSTA more than once in each eye. DURYSTA should be used with caution if you have a limited reserve of the cells lining the inner layer of the cornea.

DURYSTA should be used with caution if you have narrow or obstructed iridocorneal angles (the space where the iris, the colored part of the eye, and cornea meet).

DURYSTA may cause swelling of the macula, the center spot of the retina (back of the eye). DURYSTA should be used with caution if your eye does not have a lens, if you have an artificial lens and a torn posterior lens capsule, or if you have any risk factors for swelling of the macula.

DURYSTA may cause inflammation inside the eye or make existing inflammation worse.

DURYSTA may cause increased brown coloring of the iris, which may be permanent.

Eye injections have been associated with infections in the eye. It is important that you contact your doctor right away if you think you might be experiencing any side effects after an injection, including eye redness, sensitivity to light, eye pain, or a change in vision. Your doctor should monitor you following DURYSTA administration.

The most common side effect involving the eyes reported in patients using DURYSTA was eye redness. Other common side effects reported were feeling like something is in the eye, eye pain, being sensitive to light, a blood spot on the white of the eye, dry eye, eye irritation, increased eye pressure, a loss of cells on the inner layer of the cornea, blurry vision, inflammation of the iris, and headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please see accompanying full Prescribing Information or visit https://www.rxabbvie.com/pdf/durysta_pi.pdf

References: 1. DURYSTA® Prescribing Information. **2.** Data on file, Allergan. **3.** Data on file, AbbVie, Inc. ABVRRTI74591

Allergan an AbbVie company

US-DUR-220152 09/2022 016467